Open access · CC-BY
via OpenAlex
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease
Diana L. Price, Maya A. Koike, Asma Khan, Wolfgang Wrasidlo, Edward M. Rockenstein, Eliezer Masliah, Douglas W. Bonhaus
Scientific Reports · 2018 · ▲ 165 citations
Abstract
Accumulation of alpha-synuclein (ASYN) in neurons and other CNS cell types may contribute to the underlying pathology of synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Multiple Systems Atrophy (MSA). In support of this hypothesis for PD, ASYN immunopositive aggregates are a prominent pathological feature of PD, and mutations and gene multiplications of human wild type (WT) ASYN cause rare familial autosomal-dominant forms of PD. Targeted therapeutics that reduce the accumulation of ASYN could prevent or slow the neurodegenerative processes in PD and other synucleinopathies. NPT200-11 is a novel small molecule inhibitor of ASYN misfolding and aggregation. The effects of NPT200-11 on ASYN neuropathology were evaluated in animal models over expressing human alpha synuclein. Longitudinal studies using retinal imaging in mice expressing a hASYN::GFP fusion protein revealed that 2 months of once daily administration of NPT200-11 (5 mg/kg IP) resulted in a time-dependent and progressive reduction in retinal ASYN pathology. The effects of NPT200-11 on ASYN pathology in cerebral cortex and on other disease-relevant endpoints was evaluated in the Line 61 transgenic mouse model overexpressing human wild type ASYN. Results from these studies demonstrated that NPT200-11 reduced alpha-synuclein pathology in cortex, reduced associated neuroinflammation (astrogliosis), normalized striatal levels of the dopamine transporter (DAT) and improved motor function. To gain insight into the relationship between dose, exposure, and therapeutic benefit pharmacokinetic studies were also conducted in mice. These studies demonstrated that NPT200-11 is orally bioavailable and brain penetrating and established target plasma and brain exposures for future studies of potential therapeutic benefit.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/s41598-018-34490-9
- Canonical
- link ↗
- Fetched
- 2026-10-27 MST
Cite this
APA
Price, D.L., Koike, M.A., Khan, A., Wrasidlo, W., Rockenstein, E.M., Masliah, E., & Bonhaus, D.W. (2018). The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease. <em>Scientific Reports</em>. https://doi.org/10.1038/s41598-018-34490-9
Vancouver
Price DL, Koike MA, Khan A, Wrasidlo W, Rockenstein EM, Masliah E, et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease. Scientific Reports. 2018. doi:10.1038/s41598-018-34490-9.
BibTeX
@article{diana2018Thesma,
title = {The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease},
author = {Diana L. Price and Maya A. Koike and Asma Khan and Wolfgang Wrasidlo and Edward M. Rockenstein and Eliezer Masliah and Douglas W. Bonhaus},
journal = {Scientific Reports},
year = {2018},
doi = {10.1038/s41598-018-34490-9},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cell Death and Disease 2012
Open access · CC-BY
Alpha-synuclein: from secretion to dysfunction and death
Nature Reviews Molecular Cell Biology 2023
Preprint · OA
Mechanisms and pathology of protein misfolding and aggregation
Frontiers in Neurology 2022
Open access · CC-BY
Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
Experimental Neurology 2003
Preprint · OA
Age-dependent synuclein pathology following traumatic brain injury in mice
bioRxiv (Cold Spring Harbor Laboratory) 2026
Preprint · CC-BY
Alpha-synuclein and neuromelanin converge to promote Parkinsons disease pathology
Journal of Neurology Neurosurgery & Psychiatry 2002
Open access · OA